X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1964) 1964
Publication (106) 106
Book Review (36) 36
Dissertation (13) 13
Book Chapter (7) 7
Book / eBook (2) 2
Web Resource (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hypercholesterolaemia (1181) 1181
humans (1010) 1010
male (803) 803
female (680) 680
middle aged (557) 557
familial hypercholesterolaemia (536) 536
adult (508) 508
index medicus (418) 418
cholesterol (390) 390
hypercholesterolemia (351) 351
aged (309) 309
atherosclerosis (293) 293
cholesterol - blood (275) 275
cardiac & cardiovascular systems (254) 254
risk factors (251) 251
cholesterol, ldl - blood (235) 235
hypercholesterolemia - drug therapy (224) 224
animals (205) 205
hyperlipoproteinemia type ii - genetics (201) 201
hypercholesterolemia - blood (193) 193
peripheral vascular disease (190) 190
anticholesteremic agents - therapeutic use (188) 188
pharmacology & pharmacy (188) 188
statins (185) 185
hyperlipoproteinemia type ii - blood (179) 179
medicine, general & internal (175) 175
adolescent (160) 160
lipids (157) 157
lipids - blood (142) 142
simvastatin (142) 142
triglycerides - blood (140) 140
hypercholesterolaemia, treatment (139) 139
coronary-heart-disease (137) 137
hyperlipoproteinemia type ii - drug therapy (127) 127
disease (126) 126
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (126) 126
hypertension (126) 126
mutation (125) 125
risk (125) 125
coronary heart disease (122) 122
medicine, research & experimental (116) 116
child (114) 114
low density lipoproteins (114) 114
cardiovascular disease (113) 113
pravastatin (112) 112
treatment outcome (111) 111
cholesterol, hdl - blood (108) 108
genetic aspects (106) 106
hyperlipoproteinemia type ii - diagnosis (106) 106
hypercholesterolemia - complications (105) 105
lipoproteins (103) 103
atorvastatin (102) 102
receptors, ldl - genetics (102) 102
prevalence (100) 100
diagnosis (99) 99
low-density-lipoprotein (96) 96
heterozygote (94) 94
medicine & public health (93) 93
cardiovascular-disease (91) 91
prevention (91) 91
diet (90) 90
efficacy (90) 90
familial hypercholesterolemia (90) 90
double-blind method (88) 88
density-lipoprotein cholesterol (87) 87
hypercholesterolemia - physiopathology (79) 79
plasma (79) 79
diabetes (78) 78
mortality (78) 78
cardiovascular (77) 77
children (76) 76
heart-disease (76) 76
nutrition & dietetics (76) 76
rabbits (75) 75
analysis (73) 73
rats (73) 73
time factors (72) 72
hypertriglyceridaemia (71) 71
ezetimibe (70) 70
lipoproteins - blood (70) 70
myocardial-infarction (70) 70
risk-factors (69) 69
safety (69) 69
hyperlipoproteinemia type ii - complications (68) 68
hyperlipoproteinemia type ii - therapy (68) 68
lipoproteins, ldl - blood (66) 66
hypercholesterolemia - metabolism (65) 65
internal medicine (65) 65
endocrinology & metabolism (64) 64
obesity (64) 64
cardiovascular diseases (63) 63
homozygote (62) 62
therapy (62) 62
lipoprotein (61) 61
men (61) 61
mutations (61) 61
biochemistry & molecular biology (60) 60
ldl cholesterol (60) 60
population (60) 60
pharmacology/toxicology (59) 59
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1856) 1856
French (34) 34
Spanish (34) 34
German (19) 19
Czech (11) 11
Polish (7) 7
Slovak (6) 6
Italian (5) 5
Portuguese (5) 5
Japanese (2) 2
Swedish (2) 2
Turkish (2) 2
Chinese (1) 1
Dutch (1) 1
Hungarian (1) 1
Korean (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Paediatrics and International Child Health, ISSN 2046-9047, 10/2016, Volume 36, Issue 4, pp. 243 - 247
Homozygous familial hypercholesterolaemia (HoFH) is an inherited disease causing an approximately fourfold increase in blood low-density lipoprotein... 
HeFH, heterozygous familial hypercholesterolaemia, is caused by one mutant allele of genes affecting LDLR activity | ADH, autosomal dominant hypercholesterolaemia, refers to hypercholesterolaemia owing to a single mutation of an allele of a gene affecting LDLR activity | PCSK9, a protein called proprotein convertase subtilisin/kexin type 9, increases the rate of degradation of LDLR | Lomitapide | APOB, apolipoprotein B, is the main protein component of LDL and is the ligand for LDL receptors in the liver | FH, familial hypercholesterolaemia, is an inherited condition causing reduced LDLR activity with consequent hypercholesterolaemia | PCSK9 | LDLRAP1, a protein called LDLR adaptor protein 1, facilitates LDLR function | Lipoprotein apheresis | Microsomal triglyceride transfer protein is an enzyme involved in the hepatic assembly of triglyceride, cholesterol and APOB into triglyceride-rich particles which are secreted by the liver. These particles are metabolised to LDL | Evolucomab | LDL, low-density lipoprotein, is a complex of cholesterol attached to a lipoprotein particle which is removed from blood mainly by the liver | Homozygous familial hypercholesterolaemia | HoFH, homozygous familial hypercholesterolaemia is caused by two mutant alleles of genes affecting LDLR activity | ARH, autosomal recessive hypercholesterolaemia, refers to hypercholesterolaemia owing to a mutation of both alleles of a single gene affecting LDLR activity | LDLR, LDL receptors, mediate LDL uptake by the liver | LDLC, LDL cholesterol, refers to the cholesterol component of LDL | Liver transplantation | PEDIATRICS | Hyperlipoproteinemia Type II - complications | Atherosclerosis - etiology | Hyperlipoproteinemia Type II - therapy | Anticholesteremic Agents - therapeutic use | Atherosclerosis - therapy | Humans | Hyperlipoproteinemia Type II - diagnosis | Organ Transplantation
Journal Article
European heart journal, ISSN 0195-668X, 2015, Volume 36, Issue 43, pp. 2996 - 3003
Journal Article
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, ISSN 1098-3015, 05/2017, Volume 20, Issue 5, p. A270
Journal Article
by Vallejo-Vaz, Antonio J and Akram, Asif and Kondapally Seshasai, Sreenivasa Rao and Cole, Della and Watts, Gerald F and Hovingh, G. Kees and Kastelein, John J.P and Mata, Pedro and Raal, Frederick J and Santos, Raul D and Santos, Lourdes E and Soran, Handrean and Freiberger, Tomas and Abifadel, Marianne and Aguilar-Salinas, Carlos A and Alnouri, Fahad and Alonso, Rodrigo and Al-Rasadi, Khalid and Banach, Maciej and Bogsrud, Martin P and Bourbon, Mafalda and Bruckert, Eric and Car, Josip and Ceska, Richard and Corral, Pablo and Descamps, Olivier and Dieplinger, Hans and Do, Can T and Durst, Ronen and Ezhov, Marat V and Fras, Zlatko and Gaita, Dan and Gaspar, Isabel M and Genest, Jaques and Harada-Shiba, Mariko and Jiang, Lixin and Kayikcioglu, Meral and Lam, Carolyn S.P and Latkovskis, Gustavs and Laufs, Ulrich and Liberopoulos, Evangelos and Lin, Nan and Lin, Jie and Maher, Vincent and Majano, Nelson and Marais, A. David and März, Winfried and Mirrakhimov, Erkin and Miserez, André R and Mitchenko, Olena and Nawawi, Hapizah and Nilsson, Lennart and Nordestgaard, Børge G and Paragh, György and Petrulioniene, Zaneta and Pojskic, Belma and Reiner, Željko and Sahebkar, Amirhossein and Schunkert, Heribert and Shehab, Abdullah and Slimane, M. Naceur and Stoll, Mario and Su, Ta-Chen and Susekov, Andrey and Tilney, Myra and Tomlinson, Brian and Tselepis, Alexandros D and Vohnout, Branislav and Widén, Elisabeth and Yamashita, Shizuya and Catapano, Alberico L and Ray, Kausik K and EAS Familial Hypercholesterolaemia and EAS Familial Hypercholesterolaemia Studies Collaboration and Avdelningen för kardiovaskulär medicin and Medicinska fakulteten and Region Östergötland and Linköpings universitet and Institutionen för medicin och hälsa and Hjärt- och Medicincentrum and Kardiologiska kliniken US
Atherosclerosis (Supplements) (Component), ISSN 1567-5688, 12/2016, Volume 22, pp. 1 - 32
Journal Article
Atherosclerosis, ISSN 0021-9150, 11/2019, Volume 290, pp. 44 - 51
In 2008, the National Institute of Health and Care Excellence in the UK recommended that patients undergoing lipoprotein apheresis (LA) should be included in... 
Cardiovascular events | Heterozygous familial hypercholesterolaemia | Lipoprotein (a) | Lipoprotein apheresis | Homozygous familial hypercholesterolaemia
Journal Article
Atherosclerosis, ISSN 0021-9150, 11/2019, Volume 290, pp. 1 - 8
This consensus statement on the management of children and young people with heterozygous familial hypercholesterolaemia (FH) addresses management of... 
Children and young people | Statin treatment | Heterozygous familial hypercholesterolaemia | Familial hypercholesterolaemia | Lifestyle advice
Journal Article
Atherosclerosis, ISSN 0021-9150, 11/2019, Volume 290, pp. 138 - 139
Journal Article
European Heart Journal, ISSN 0195-668X, 2014, Volume 35, Issue 32, pp. 2146 - 2157
Journal Article
Atherosclerosis, ISSN 0021-9150, 2017, Volume 260, pp. 47 - 55
Journal Article
Journal Article
Atherosclerosis, ISSN 0021-9150, 03/2018, Volume 270, pp. 117 - 122
Journal Article
Journal of Atherosclerosis and Thrombosis, ISSN 1340-3478, 2016, Volume 23, Issue 8, pp. 891 - 900
Familial hypercholesterolemia (FH) is the most common and serious form of inherited hyperlipidaemia. Dominantly inherited with high penetrance, untreated FH... 
Asia-Pacific | Translational research | Familial hypercholesterolaemia | Asia-pacific
Journal Article
Atherosclerosis, ISSN 0021-9150, 2013, Volume 229, Issue 1, pp. 161 - 168
Journal Article